159 related articles for article (PubMed ID: 36585791)
1. Effect of tenofovir containing ART on renal function in patients with moderate/severe reduced creatinine clearance at baseline: A retrospective study at two referral hospitals in Namibia.
Kalemeera F; Godman B; Stergachis A; Rennie T
Pharmacol Res Perspect; 2023 Feb; 11(1):e00681. PubMed ID: 36585791
[TBL] [Abstract][Full Text] [Related]
2. Effect of TDF-containing regimens on creatinine clearance in HIV patients in Namibia with a baseline CrCl <60ml/min; findings and implications.
Kalemeera F; Godman B; Stergachis A; Rennie T
Hosp Pract (1995); 2020 Feb; 48(1):35-40. PubMed ID: 31829065
[No Abstract] [Full Text] [Related]
3. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
Gupta SK; Anderson AM; Ebrahimi R; Fralich T; Graham H; Scharen-Guivel V; Flaherty JF; Fortin C; Kalayjian RC; Rachlis A; Wyatt CM
PLoS One; 2014; 9(3):e92717. PubMed ID: 24651857
[TBL] [Abstract][Full Text] [Related]
4. Switching from tenofovir containing regimens to boosted protease inhibitor monotherapy: Impact on renal function.
Estébanez M; Bernardino JI; Serrano L; Pérez-Valero I; Zamora FX; Montes-Ramírez ML; González-García JJ; Arribas JR
Enferm Infecc Microbiol Clin; 2016 Jan; 34(1):29-32. PubMed ID: 25735716
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi.
Johnson DC; Chasela C; Maliwichi M; Mwafongo A; Akinkuotu A; Moses A; Jamieson DJ; Kourtis AP; King CC; van der Horst C; Hosseinipour MC
PLoS One; 2012; 7(7):e41011. PubMed ID: 22848422
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana.
Nartey ET; Tetteh RA; Yankey BA; Mantel-Teeuwisse AK; Leufkens HGM; Dodoo ANO; Lartey M
BMC Res Notes; 2019 Jul; 12(1):445. PubMed ID: 31331365
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate associated nephrotoxicity: a retrospective cohort study at two referral hospitals in Namibia.
Kalemeera F; Godman B; Stergachis A; Rennie T
Pharmacoepidemiol Drug Saf; 2021 Feb; 30(2):189-200. PubMed ID: 33006803
[TBL] [Abstract][Full Text] [Related]
8. Reversibility of renal dysfunction after discontinuation of tenofovir.
Cha A; Besignano-Long AR; Rothberger N; Shah B
J Am Pharm Assoc (2003); 2016; 56(3):280-3. PubMed ID: 27067552
[TBL] [Abstract][Full Text] [Related]
9. Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis.
Mugwanya KK; Baeten JM; Wyatt C; Mugo NR; Celum CL; Ronald A; Kiarie J; Katabira E; Heffron R;
J Acquir Immune Defic Syndr; 2018 Feb; 77(2):206-211. PubMed ID: 29135656
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
[TBL] [Abstract][Full Text] [Related]
11. Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial.
Baltrusaitis K; Makanani B; Tierney C; Fowler MG; Moodley D; Theron G; Nyakudya LH; Tomu M; Fairlie L; George K; Heckman B; Knowles K; Browning R; Siberry GK; Taha TE; Stranix-Chibanda L;
BMC Infect Dis; 2022 Jul; 22(1):634. PubMed ID: 35858874
[TBL] [Abstract][Full Text] [Related]
12. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
Mulenga L; Musonda P; Mwango A; Vinikoor MJ; Davies MA; Mweemba A; Calmy A; Stringer JS; Keiser O; Chi BH; Wandeler G;
Clin Infect Dis; 2014 May; 58(10):1473-80. PubMed ID: 24585558
[TBL] [Abstract][Full Text] [Related]
13. Effects of long-term exposure to tenofovir disoproxil fumarate-containing antiretroviral therapy on renal function in HIV-positive Chinese patients.
Tan Q; He YH; Yang TT; Yan DM; Wang Y; Zhao X; Liu HX; He SH; Zhou ZH
J Microbiol Immunol Infect; 2019 Oct; 52(5):710-719. PubMed ID: 31427111
[TBL] [Abstract][Full Text] [Related]
14. Development of normal reference intervals for renal function in pregnancy: a secondary analysis of clinical trial data.
Legoabe Z; Sebitloane M; Lombard C; Naidoo M; Gray G; Moodley D
J Obstet Gynaecol; 2024 Dec; 44(1):2361445. PubMed ID: 38832538
[TBL] [Abstract][Full Text] [Related]
15. Effect of changing from first- to second-line antiretroviral therapy on renal function: a retrospective study based on data from a single health facility in Namibia.
Kalemeera F; Mbango C; Mubita M; Naikaku E; Gaida R; Godman B
Expert Rev Anti Infect Ther; 2016 Aug; 14(8):777-83. PubMed ID: 27309846
[TBL] [Abstract][Full Text] [Related]
16. Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).
Touzard Romo F; Smeaton LM; Campbell TB; Riviere C; Mngqibisa R; Nyirenda M; Supparatpinyo K; Kumarasamy N; Hakim JG; Flanigan TP
HIV Clin Trials; 2014; 15(6):246-60. PubMed ID: 25433664
[TBL] [Abstract][Full Text] [Related]
17. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
Goicoechea M; Liu S; Best B; Sun S; Jain S; Kemper C; Witt M; Diamond C; Haubrich R; Louie S;
J Infect Dis; 2008 Jan; 197(1):102-8. PubMed ID: 18171292
[TBL] [Abstract][Full Text] [Related]
18. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
[TBL] [Abstract][Full Text] [Related]
19. Low Incidence of Renal Dysfunction among HIV-Infected Patients on a Tenofovir-Based First Line Antiretroviral Treatment Regimen in Myanmar.
Kyaw NT; Harries AD; Chinnakali P; Antierens A; Soe KP; Woodman M; Das M; Shetty S; Zuu MK; Htwe PS; Fernandez M
PLoS One; 2015; 10(8):e0135188. PubMed ID: 26301416
[TBL] [Abstract][Full Text] [Related]
20. The frequency of adjusted renal dosing of tenofovir DF and its effects on patient outcomes.
Langness JA; Hindman JT; Johnson SC; Kiser JJ
J Pharm Pract; 2013 Aug; 26(4):397-400. PubMed ID: 23204147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
